Name: MOP Sample Pack ( phospho- and non-phospho-µ-Opioid Receptor Antibodies )
Price: 464.00 USD

Overview
- MOP Sample Pack consisting of all four available phospho- and one non-phospho-µ-Opioid Receptor Antibodies 5 x 20 µL trial size each. Specifically, this sample pack contains the following antibodies pT370-MOP (7TM0319B), pS375-MOP (7TM0319C), pT376-MOP (7TM0319D) pT379-MOP (7TM0319E) and MOP (non-phos, C-Term) (7TM0319N).
  
  Please contact us at for specific academic pricing.
Properties
- Host
  
  rabbit
  
  Antibody Type
  
  polyclonal
  
  Isotype
  
  IgG
  
  Reactivity
  
  human
  
  Immunogen
  
  Synthetic phospho- and non-phosphopeptides derived from human MOP.
  
  Purification
  
  Antigen affinity chromatography
  
  Formulation
  
  Liquid
  
  Storage
  
  Short-term storage at 4°C and long-term storage at -20°C
  
  Antigen
  
  MOP, OPRM1, µ-Opioid Receptor, Mu Receptor (UniProt:P35372 (human), P42866 (mouse), P33535 (rat))
  
  * This product is intended for research use only.

Applications

Application

WB

Application	Dilutions
Western Blot (WB)	1:1000

Reference
- Kliewer A, Schmiedel F, Sianati S, Bailey A, Bateman JT, Levitt ES, Williams JT, Christie MJ, Schulz S. Phosphorylation-deficient G-protein-biased μ-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects. Nat Commun. 2019 Jan 21;10(1):367. doi: 10.1038/s41467-018-08162-1.
  Miess E, Gondin AB, Yousuf A, Steinborn R, Mösslein N, Yang Y, Göldner M, Ruland JG, Bünemann M, Krasel C, Christie MJ, Halls ML, Schulz S, Canals M. Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid μ-opioid receptor desensitization. Sci Signal. 2018 Jul 17;11(539). pii: eaas9609. doi: 10.1126/scisignal.aas9609.
  Yousuf A, Miess E, Sianati S, Du YP, Schulz S, Christie MJ. Role of Phosphorylation Sites in Desensitization of µ-Opioid Receptor. Mol Pharmacol. 2015 Oct;88(4):825-35. doi: 10.1124/mol.115.098244. Epub 2015 May 12.
  Just S, Illing S, Trester-Zedlitz M, Lau EK, Kotowski SJ, Miess E, Mann A, Doll C, Trinidad JC, Burlingame AL, von Zastrow M, Schulz S. Differentiation of opioid drug effects by hierarchical multi-site phosphorylation. Mol Pharmacol. 2013 Mar;83(3):633-9. doi: 10.1124/mol.112.082875. Epub 2012 Dec 13.
  Doll C, Pöll F, Peuker K, Loktev A, Glück L, Schulz S. Deciphering µ-opioid receptor phosphorylation and dephosphorylation in HEK293 cells. Br J Pharmacol. 2012 Nov;167(6):1259-70. doi: 10.1111/j.1476-5381.2012.02080.x.
  Doll C, Konietzko J, Pöll F, Koch T, Höllt V, Schulz S. Agonist-selective patterns of µ-opioid receptor phosphorylation revealed by phosphosite-specific antibodies. Br J Pharmacol. 2011 Sep;164(2):298-307. doi: 10.1111/j.1476-5381.2011.01382.x. PubMed Central PMCID: PMC3174411.

Figure 5. Validation of the µ-Opioid Receptor in transfected HEK293 cells. Native HEK293 cells (MOCK) or HEK293 cells stably expressing the µ-Opioid Receptor (MOP) were lysed and immunoblotted with the phosphorylation-independent anti-MOP antibody (7TM0319N-WB) at a dilution of 1:1000.

MOP Sample Pack ( phospho- and non-phospho-µ-Opioid Receptor Antibodies )

MOP Sample Pack ( phospho- and non-phospho-µ-Opioid Receptor Antibodies )

We Also Recommend

AT1 Sample Pack ( phospho- and non-phospho-Angiotensin Receptor Antibodies )

pS261pS262-β2 ( phospho-β2-Adrenoceptor Polyclonal Antibody )

pS343-GPR183 ( phospho-GPR183 Polyclonal Antibody )